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SUMMARY
A central hallmark of cancer cells is the reprogram-
ming of cellular metabolism to meet the bioenergetic
and biosynthetic demands of malignant growth.
Here, we report that the miR-1792 microRNA
(miRNA) cluster is an oncogenic driver of tumormeta-
bolic reprogramming. Loss ofmiR-1792 inMyc+ tu-
mor cells leads to a global decrease in tumor cell
metabolism, affecting both glycolytic and mitochon-
drial metabolism, whereas increased miR-1792
expression is sufficient to drive increasednutrient us-
age by tumor cells.Wemapped themetabolic control
element of miR-1792 to the miR-17 seed family,
which influences cellularmetabolismandmammalian
target of rapamycin complex 1 (mTORC1) signaling
through negative regulation of the LKB1 tumor sup-
pressor. miR-17-dependent tuning of LKB1 levels
regulates both the metabolic potential of Myc+ lym-
phomas and tumor growth in vivo. Our results estab-
lishmetabolic reprogramming as a central function of
the oncogenicmiR-1792miRNA cluster that drives
the progression of MYC-dependent tumors.
INTRODUCTION
Tumor cells must manage their energetic resources to grow and
survive. This involves coordinating metabolic activities to pro-
duce ATP, and the acquisition or synthesis of macromolecules
(i.e., proteins, lipids, and nucleotides) at sufficient rates to
meet the demands of malignant growth (Lunt and Vander Hei-
den, 2011). A common characteristic of cancer cells is the
reprogramming of cellular metabolism to favor metabolic path-
ways that fuel aberrant cell growth such as aerobic glycolysis
(i.e., the Warburg effect) and mitochondrial metabolism (Vander
Heiden et al., 2009; Weinberg and Chandel, 2015). Many of the
predominant oncogenic mutations observed in cancer also
control tumor cell metabolism as part of their mode of action (De-
berardinis et al., 2008; Jones and Thompson, 2009), linking
metabolic dysregulation to tumor progression.
One of the major drivers of metabolic reprogramming in
tumor cells is the c-Myc proto-oncogene (hereafter referred
to as Myc), a transcription factor overexpressed or deregu-
lated in over 50% of human cancers including hematopoietic,
brain, breast, colorectal, and lung malignancies (Bredel et al.,
2009; Cancer Genome Research Atlas, 2012, 2014; Li et al.,
2013; Schmitz et al., 2012). Increased MYC expression is
associated with poor prognosis in Burkitt Lymphoma (BL)
(Lin et al., 2012b) and diffuse large B cell lymphoma (DLBCL)
(Barrans et al., 2010; Savage et al., 2009; Zhou et al., 2014),
with an overall 5-year survival rate of only 30% (Savage
et al., 2009).
Myc promotes the re-wiring of tumor cell metabolism through
the transcriptional regulation of metabolic pathway genes,
including enzymes that regulate glycolysis, tricarboxylic acid
(TCA) cycle metabolism, oxidative phosphorylation (OXPHOS),
and mitochondrial biogenesis (Stine et al., 2015). Oncogenic
Myc can also function as an amplifier of cellular gene expression
programs (Lin et al., 2012a; Nie et al., 2012), which may occur
through non-specific ‘‘invading’’ of enhancer and promoter re-
gions, or recruitment of specific cofactors, such as Miz1 and
Max, that help shape transcriptional responses triggered by
supraphysiological levels of oncogenic Myc (Wolf et al., 2015).
Myc also regulates the transcription of microRNAs (miRNAs),
which are small, non-coding RNAs that negatively regulate
mRNA stability and/or translation through partial complementary
base pairing to the 30 UTR of target mRNAs (Bartel, 2009). Myc
has been associated with widespread repression of miRNA
expression (Chang et al., 2008), but is also found to induce
expression of the polycistronic miRNA clustermiR-1792. Orig-
inally identified as a candidate gene in the 13q31-q32 amplifica-
tion observed in lymphoma (Ota et al., 2004), miR-1792 is a
direct transcriptional target of Myc (O’Donnell et al., 2005) and
cooperates with Myc to promote lymphomagenesis in animal
models (He et al., 2005). miR-1792 expression is elevated in
a number of human tumors, including cancers of the colon (He
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et al., 2005), lung (Hayashita et al., 2005), and DLBCL (Cerami
et al., 2012; Olive et al., 2010; Pei et al., 2013).
Recent work indicated that elevated miR-1792 expression
can maintain tumor growth even when Myc is inactivated in tu-
mors (Li et al., 2014), suggesting that miR-1792 may mediate
several of the pro-tumorigenic effects ascribed to Myc. Here,
we describe an essential function for the Myc-regulated miRNA
cluster miR-1792 in mediating Myc-driven metabolic reprog-
ramming, implicating control of tumor metabolism as a central
part of miR-1792 oncogenic activity.
RESULTS
miR-17-92 Regulates Glycolytic and Oxidative
Metabolism in Lymphoma Cells
Myc has been characterized as a master regulator of tumor
metabolism through the direct transcriptional regulation of meta-
bolic enzymes involved in intermediary metabolism (Stine et al.,
2015). However, Myc also induces the expression of miR-
1792, a polycistronic miRNA cluster which encodes six individ-
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Figure 1. The Polycistronic miRNA Cluster
miR-1792 Regulates Glycoytic and Oxida-
tive Metabolism in Myc+ Lymphoma Cells
(A) Schematic of the miR-1792 miRNA poly-
cistron. Individual mature miRNAs with highlighted
seed regions are listed, with seed families grouped
by color.
(B) Relative expression of individual miRNAs of the
miR-1792 polycistron in Em-Myc lymphoma cells
as determined by qPCR. Transcript levels were
determined relative to U6 RNA and expressed
relative to miR-17 levels (set to 1).
(C) ECAR and OCR of Em-Myc lymphoma cells
expressing (fl/fl) or lacking (D/D) miR-1792.
(D) Relative glucose consumption and lactate
production by fl/fl andD/D Em-Myc lymphoma cells
after 48 hr of culture.
(E) Relative glutamine consumption and ammonia
production by lymphoma cells grown as in (D).
(F) ECAR and OCR of Raji cells ectopically ex-
pressing the entire miR-1792 cluster (1792) or
empty vector control (Ctrl).
(G) Relative glucose consumption and lactate
production by Raji cells expressing control (Ctrl) or
miR-1792 expression (1792) vectors after 48 hr
of culture.
(H) Relative glutamine consumption and ammonia
production by Raji cells grown as in (G).
*p < 0.05; **p < 0.01; ***p < 0.001.
ual miRNAs from a single RNA precursor
(Figure 1A) (Olive et al., 2013). To inves-
tigate the influence of miR-1792 on
the metabolism of Myc+ tumor cells, we
used established Em-Myc B cell lym-
phomas harboring conditional floxed
alleles of miR-1792 (miR-1792fl/fl, de-
noted hereafter as fl/fl) (Mu et al., 2009).
Examination of miRNA expression re-
vealed miR-17, miR-20, and miR-92a as
the most abundant mature miRNAs of the cluster expressed in
Em-Myc lymphoma cells (Figure 1B). Parental fl/fl Em-Myc lym-
phoma cells were cultured with 4-OHT to generate isogenic
tumor cells with homozygous deletion of miR-1792 (miR-
1792D/D, denoted as D/D) (Figures S1A and S1B). We did
not observe compensation of mature miRNA expression from
the paralogous clusters miR-106a363 or miR-106b25 in
lymphoma cells lacking miR-1792 (Figure S1C). Deletion of
miR-1792 led to a slight reduction in Em-Myc lymphoma cell
proliferation as previously described (Mu et al., 2009) but did
not significantly alter tumor cell viability (Figures S1D and S1E).
We next assessed the impact of miR-17-92 deletion on the
metabolism ofMyc+ lymphomas by measuring their extracellular
acidification rate (ECAR), a measure of aerobic glycolysis, and
oxygen consumption rate (OCR), a measure of OXPHOS (Wu
et al., 2007). D/D lymphomas displayed an 50% reduction in
both their ECAR and OCR compared to parental fl/fl lymphoma
cells (Figure 1C). Consistent with the reduction in aerobic
glycolysis, D/D lymphomas displayed lower glucose uptake
and lactate production compared to lymphomas expressing
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miR-1792 (Figure 1D). Glutamine consumption and ammonia
production (a measure of glutaminolysis) were similarly reduced
in D/D lymphoma cells (Figure 1E). The expression of key meta-
bolic enzymes involved in glycolysis (Hk2, Aldolase, Ldha) and
glutaminolysis (Gls1, Gls2) were reduced in D/D lymphoma cells
compared to fl/fl controls (Figure S1F). Proliferating D/D lym-
phoma cells also displayed reduced cell size relative to parental
tumor cells (Figure S1G).
miR-1792 cooperates with Myc to promote lymphomagene-
sis and tumor progression in animal models (He et al., 2005). To
assess whether overexpression of miR-1792 was sufficient
to alter the metabolic activity of lymphoma cells, we ectopically
expressed miR-1792 in Raji cells (Figure S1H), a human
BL cell line harboring a t(8;14)(q24;q32) MYC-IGH translocation
(Hamlyn and Rabbitts, 1983). Ectopic expression of miR-
1792 increased the proliferative capacity but not the viability
of Raji cells in culture (Figures S1I and S1J). In contrast to miR-
1792 deletion, ectopic expression of miR-1792 increased
both the ECAR and OCR of Raji cells (Figure 1F). We observed
similar increases in both glucose consumption and lactate pro-
duction (Figure 1G) and glutaminolysis (Figure 1H) in Raji cells
overexpressing miR-1792. Together these data indicate that
miR-1792 is both sufficient to drive enhanced metabolism
and required for global maintenance of glycolytic and oxidative
metabolism in Myc-dependent lymphoma cells.
miR-1792 Is a Global Regulator of Myc-Dependent
Metabolic Reprogramming
We next set out to identify pathways under miR-1792 control
by conducting RNA sequencing (RNA-seq) analysis of isogenic
lymphoma cells expressing (fl/fl) or lacking (D/D) miR-1792.
Deletion of miR-1792 promoted widespread changes in gene
expression in Myc+ lymphoma, with the expression of >5,700
genes significantly altered in D/D lymphomas relative to control
cells (Figure S2A; Table S1). Analysis of KEGG pathways signif-
icantly decreased in D/D lymphomas revealed enrichment in
metabolic pathway genes, mRNA transport and translation,
and proteasome and peroxisome pathway components (Fig-
ure 2A). Further analysis of the metabolic pathways genes influ-
enced by miR-1792 revealed a global decrease in metabolic
pathways including glycolysis, the TCA cycle (Figure S2B), com-
ponents of the electron transport chain (Figure S2C), amino acid
metabolism, the pentose phosphate pathway, serine biosyn-
thesis, and nucleotide biosynthesis (Figure 2A). We next as-
sessed overlap between the miR-1792-regulated transcrip-
tome and known Myc target genes (Kim et al., 2010). This
analysis revealed that 45% of defined Myc target genes were
significantly influenced by loss of miR-1792 (Figure 2B). En-
riched in this group ofmiR-1792-dependent Myc-target genes
were metabolic pathway genes involved in central carbon meta-
bolism and cellular biosynthesis (i.e., amino acid, purine, and
pyrimidine biosynthesis). Details of differentially expressed
miR-1792-dependent Myc-target genes are summarized in
Figure S2D and Table S2.
We next assessed the impact ofmiR-1792 loss onmetabolic
network connectivity in Myc-dependent lymphoma cells. This
analysis, which is based on connectivity between metabolite
abundance and metabolic enzyme gene expression (Jha et al.,
2015; Vincent et al., 2015b), revealed several metabolic sub-net-
works dependent on miR-1792 expression (Figure 2C). This
network-based analysis confirmed a global downregulation
of cellular metabolic pathways at the transcriptional level in
D/D lymphomas. Pathways decreased in miR-1792-deficient
Em-Myc lymphoma cells included glycolysis, and key branching
pathways from the glycolytic pathway supporting nucleotide
biosynthesis (i.e., pentose phosphate and serine biosynthesis
pathways). The network also revealed lower TCA cycle meta-
bolism and glutathione biosynthesis in miR-1792-deficient
lymphomas, while highlighting increases in genes associated
with inositol biosynthesis and acetate metabolism (Acss1 and
Aldh3b1). Taken together, these data suggest an active role
for miR-1792 in enforcing the Myc-dependent metabolic
transcriptome.
Myc-Dependent Regulation of Central Carbon
Metabolism RequiresmiR-1792
Given the decreased glycolytic and oxidative metabolism of
Myc+ lymphoma cells lacking miR-1792 (Figure 1), we con-
ducted stable isotope tracer analysis (SITA) on fl/fl and D/D
Em-Myc lymphoma cells by culturing them with either U-[13C]-
glucose or -glutamine. D/D lymphoma cells displayed deceased
overall abundance of intracellular metabolites involved in central
carbon metabolism (Figure 3A). Total intracellular pyruvate and
lactate levels were decreased by 50% in D/D Em-Myc cells
(Figure 3A), due largely to reduced production of 13C3-pyruvate
and 13C3-lactate isotopologues from glucose (Figure 3B). Simi-
larly, the total abundance of TCA cycle metabolites including
citrate and fumarate, as well as the incorporation of 13C-
glucose-derived carbon into these metabolite pools, were
decreased in D/D cells relative to control lymphoma cells (Fig-
ures 3A and 3B). The synthesis of glutamate from a-ketogluta-
rate, which is mediated by glutamate dehydrogenase (GLDH)
in Myc-driven cancer cells (Bott et al., 2015), was similarly
decreased in Myc+ lymphoma cells lacking miR-1792 (Fig-
ure 3A). We observed a significant abundance of 13C3 isoto-
pologues of citrate, fumarate, and glutamate (blue bar, m+3),
suggesting contribution of pyruvate carboxylase (PC) activity
to TCA cycle anaplerosis in Em-Myc lymphoma cells (Figure 3B).
Decreased mRNA levels for the glucose transporters Glut1
(Slc2a1) and Glut3 (Slc2a3) were observed in D/D Em-Myc cells
(Figure S3), which may contribute to lower glucose utilization by
these cells.
Myc is a major regulator of glutaminolysis (Gao et al., 2009;
Wise et al., 2008) and regulates glutamine-dependent TCA cycle
activity under basal and hypoxic conditions (Le et al., 2012).
However, we found that miR-1792 was required to support
glutamine-dependent TCA cycle anaplerosis in Em-Myc lym-
phoma cells (Figure 3C). Incorporation of U-[13C]-glutamine
carbon into TCA intermediates was significantly reduced in
D/D Em-Myc lymphoma cells, both in terms of total abundance
(Figure 3C) and isotopomer distribution (Figure 3D). Of note,
glutamine-dependent production of 13C-citrate and 13C-aspar-
tate, which play essential roles in supporting cancer cell prolifer-
ation (Birsoy et al., 2015; Hatzivassiliou et al., 2005; Sullivan
et al., 2015), were significantly reduced in D/D Em-Myc lym-
phoma cells.
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Figure 2. miR-1792 Is a Global Regulator of Metabolism Downstream of Myc
(A) List of KEGG pathways significantly enriched in parental control (fl/fl) versus miR-1792-deficient (D/D) Em-Myc lymphoma cells (q value <0.1) using the
Benjamini-Hochberg method.
(B) Analysis of Myc target genes differentially expressed in Em-Myc lymphoma cells lackingmiR-1792. Top, Venn diagram depicting all differentially expressed
genes enriched in fl/fl versus D/D Em-Myc lymphoma cells (5779) and overlap with Myc target genes (1610). Bottom, KEGG pathway analysis of
miR-1792-dependent Myc target genes.
(legend continued on next page)
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miR-17 and -20 Drive Metabolic Reprogramming
Downstream of Myc
Given that the miR-1792 gene encodes six mature miRNAs
comprising four seed families (Figure1A),wenext sought todeter-
minewhichmiRNAscontribute to themetabolic regulatory activity
of the cluster. We engineered a series of miR-1792-deficient
Em-Myc lymphoma cell lines re-expressing the full miRNA cluster
(+1792) or mutantmiR-1792 alleles lacking specific seed fam-
ily members (Figure 4A). The relative expression of each mature
miRNA in control (fl/fl) andmiR-1792mutant cell lines was veri-
fied by qPCR (Figure S4A). Seahorse analysis of these lymphoma
cell lines revealed differential contributions of each miR-1792
seed family to the bioenergetic profiles of Em-Myc lymphomacells
(Figure 4B). Addback of the full miR-1792 cluster rescued the
OCR and enhanced the ECAR of D/D cells, confirming our earlier
results that elevatedmiR-1792 expression can enhance glycol-
ysis (Figures 1F and 1G). Addback of the cluster lacking onlymiR-
92a (D92) ormiR-19a andmiR-19b (D19a,b) increased both OCR
and ECAR above levels seen in fl/fl cells, whereas addback of a
mutant miR-1792 allele lacking the miR-17 family members
miR-17 and miR-20a (D17,20) failed to rescue the ECAR and
OCR of D/D cells (Figure 4B).
Further metabolic profiling was conducted using individual
D/D lymphoma cell clones expressing all components of
(C) Integrated metabolic network analysis for fl/fl versus D/D Em-Myc lymphoma cells. The direction and magnitude of fold changes in enzyme expression or
metabolite abundance between conditions is indicated on a green (enriched in fl/fl) to red (enriched in D/D) color scale. Enzymes are represented by connecting
lines between metabolites, with the color of the edge indicating the fold change and the thickness reflecting the significance of differential expression. Round
nodes represent metabolites, with the differential abundance of each metabolite indicated by the size of the node.
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Figure 3. Regulation of Central Carbon Metabolism by miR-1792
(A) Relative abundance of U-[13C]-glucose-derived metabolites from fl/fl and D/D Em-Myc lymphoma cells. Cells were cultured for 2 hr in medium containing
U-[13C]-glucose (25 mM) and unlabeled glutamine (2 mM), and the proportion of 13C-labeled (black bar) or unlabeled (12C, white bar) metabolites was determined
by GC-MS. The height of the bar represents the total abundance of each metabolite, with the black bar representing the fraction of the metabolite pool derived
from U-[13C]-glucose.
(B) Mass isotopomer distribution (MID) of glycolytic intermediates (pyruvate, lactate), TCA cycle intermediates (citrate, fumarate), and glutamate for fl/fl and D/D
Em-Myc lymphoma cells, cultured as in (A).
(C) Relative abundance of U-[13C]-glutamine-derived metabolites from fl/fl and D/D Em-Myc lymphoma cells. Cells were cultured for 2 hr with U-[13C]-glutamine
(2 mM) and unlabeled glucose (25 mM), and the proportion of 13C-labeled (gray bar) or unlabeled (12C, white bar) metabolites determined by GC-MS.
(D) MID of U-[13C]-glutamine-derived metabolites in fl/fl and D/D Em-Myc lymphoma cells, cultured as in (C).
*p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 4. The miR-17 Family Members miR-17 and miR-20a Are Required for miR-1792-Dependent Metabolic Reprograming
(A) Schematic of miR-1792 constructs lacking individual seed families used in this study.
(B) OCR versus ECAR plot for fl/fl and D/D Em-Myc lymphoma cells, as well as D/D lymphomas expressing miR-1792 addback constructs described in (A).
(CandD)Relative glucoseconsumption (C) and lactateproduction (D)of control (fl/fl,whitebar),miR-1792-deficient (D/D, blackbar), ormiR-17/20-deficient (+D17/
20, blue bars) Em-Myc lymphoma cells after 48 hr of culture. D/D lymphoma cells re-expressing the entiremiR-1792 polycistron (+1792, gray bar) are included.
(E) Immunoblot of metabolic enzyme expression from lysates of Em-Myc lymphoma cells described in (B). Actin levels are shown as a control for protein loading.
HK2, hexokinase-2; LDHA, lactate dehydrogenase A; GLS2, glutaminase-2.
(legend continued on next page)
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miR-1792 except miR-17 and miR-20a (D17,20). Lymphoma
cells lacking miR-17/20 displayed similar reductions in glucose
consumption (Figure 4C), lactate production (Figure 4D), gluta-
mine consumption (Figure S4B), and ammonia production
(Figure S4C) compared to D/D lymphoma cells, which was
fully rescued only through addback of the fullmiR-1792 cluster.
The reduction in glycolysis and glutaminolysis correlated with
reduced levels of key glycolysis (Hk2, Aldolase, Ldha) and
glutaminolysis (Gls2) enzymes in D17,20 lymphoma cells rela-
tive to control cells (either fl/fl or full miR-1792 addback)
(Figure 4E).
We next used SITA to assess whether the miR-17 seed
family influences nutrient utilization by Myc+ lymphoma cells.
Control (fl/fl), miR-1792-deficient (D/D), miR-1792 addback,
or D17,20 lymphoma cells were cultured in medium containing
either U-[13C]-glucose or -glutamine, and metabolite abun-
dances determined by gas chromatography-mass spectrometry
(GC-MS). Re-expression ofmiR-1792 was sufficient to restore
both glucose- and glutamine-dependent metabolic flux in D/D
lymphoma cells (Figures 4F, 4G, and S4D–S4G). Ectopic
miR-1792 expression actually enhanced metabolic flux in
D/D lymphoma cells beyond control levels, marked by increased
production of lactate from 13C-glucose (Figure 4F) and TCA cy-
cle metabolites from 13C-glutamine (Figures 4G and S4G). In
contrast, D17,20 lymphoma cells displayed similar 13C-labeling
patterns to D/D lymphoma cells (Figures 4F and 4G).
Finally, we assessed the contribution of miR-17/20 to the
tumorigenic potential of Em-Myc lymphomas. While re-expres-
sion of full-length miR-1792 restored the proliferative capacity
of D/D lymphoma cells to control levels, D17,20 failed to rescue
lymphoma cell proliferation in vitro (Figure 4H). Next, we injected
nude mice with control (fl/fl) or miR-1792-deficient Em-Myc
lymphoma cells expressing full-length miR-1792 or D17,20,
andmonitored palpable tumor formation over time.While control
lymphomas and D/D lymphomas re-expressing miR-1792
formed tumors rapidly (median onset of2 weeks), the develop-
ment of tumors lacking miR-17 and -20 (D17,20) was signifi-
cantly slower, with an average latency of 4 weeks (Figure 4I).
For one clone in particular (D17,20-2), >30% of animals re-
mained tumor-free for up to 8 weeks, compared to 50% for
animals who had received D/D lymphoma cells (Figure 4I).
LKB1 Is a Direct Target of themiR-17 Seed Family
miRNAs act to repress mRNA translation or promote mRNA
degradation via partial complementary binding to the 30 UTR of
target mRNAs (Fabian et al., 2010). Previous work has linked de-
regulated miR-19 expression to the lipid phosphatase Pten (Mu
et al., 2009; Olive et al., 2009), which may affect glycolysis
throughmodulation of PI3K-Akt signaling. However, Pten protein
levels were unaffected by loss of miR-1792 in D/D lymphoma
cells (Figure S5A), and lymphoma cells lacking miR-19 did not
display major changes in ECAR or OCR (Figure 4B).
We used the miRNA prediction algorithm Targetscan (Agarwal
et al., 2015) and curated miRNA-mRNA interactions (Helwak
et al., 2013) to identify Stk11, which encodes the serine-threo-
nine kinase Liver Kinase B1 (LKB1), as a putative miR-17 family
target. Previous work had identified LKB1 as a potential target of
miR-17 in ovarian cancer cells (Liu et al., 2015). The seed region
of miR-17/20 was predicted to bind to one site (base pairs 122–
130) in the mouse Stk11 30 UTR sequence (Figure 5A), and that
this 30 UTR target site was retained across several mammalian
species including humans (Figure S5B). This was intriguing given
that haploinsufficiency of LKB1, rather than biallelic inactivation
of the gene, is commonly associated with tumor development
(Vaahtomeri and Ma¨kela¨, 2011). LKB1 is also a negative regular
of tumor metabolism whose loss promotes the Warburg effect in
tumors (Faubert et al., 2014; Shackelford et al., 2009). We con-
ducted 30-rapid amplification of cDNA end (RACE) using mRNA
isolated from Em-Myc lymphoma cells and, consistent with pre-
vious reports (Smith et al., 1999), found that Stk11 possesses an
alternative poly-adenylation sequence that gives rise to both
short and long 30 UTR isoforms (denoted S1 and L1, for short
and long, respectively) that contain the miR-17/20 targeting
sequence (Figure S5C).
We next assessed whether miR-17 directly acts on the
30 UTR of Stk11 mRNA to regulate its expression. We first
used a reporter assay in which the Stk11 30 UTR was cloned
downstream of a luciferase reporter gene to assess miRNA-
dependent suppression of the 30 UTR sequence. Normalized
luciferase activity was reduced in 293T cells expressing either
the S1 or L1 form of the Stk11 30 UTR (Figure S5D), indicating
suppression of this 30 UTR by endogenous miRNAs or other
RNA binding proteins. The Stk11 30 UTRs were suppressed
further by ectopic expression of miR-17 (Figure 5B). Mutating
the complementary miR-17 target site (Figure 5A) abolished
miR-17-dependent regulation of the Stk11 30 UTR in this assay
(Figures 5B and S5D).
We next expressed FLAG-tagged versions of LKB1 in 293T
cells using expression constructs encoding Stk11 mRNA with
no 30 UTR (D), wild-type 30 UTR (WT), or amutated 30 UTR lacking
complementarity with the miR-17 seed region (MUT) (Fig-
ure S5E). Protein levels of FLAG-LKB1 were reduced in cells ex-
pressing the wild-type Stk11 30 UTR when co-transfected with a
miR-17 expression vector (Figure 5C). Conversely, FLAG-LKB1
with the mutant Stk11 30 UTR was refractory to miR-17 expres-
sion (Figure 5C).
(F) Relative abundance of U-[13C]-glucose-derived metabolites in fl/fl, D/D, miR-17/20-deficient (+D17/20), and miR-1792-expressing (+1792) Em-Myc
lymphoma cells. Cells were cultured for 2 hr with U-[13C]-glucose, and the proportion of 13C-labeled (black bar) or unlabeled (12C, white bar) metabolites was
determined by GC-MS.
(G) Relative abundance of U-[13C]-glutamine-derived metabolites in Em-Myc lymphoma cells described in (F). Cells were cultured for 2 hr with U-[13C]-glutamine,
and the proportion of 13C-labeled (gray bar) or unlabeled (12C, white bar) metabolites was determined by GC-MS.
(H) Growth curves of control (fl/fl), miR-1792-deficient (D/D+Ctrl), miR-17/20-deficient (D/D+D17/20), and miR-1792-expressing (D/D+1792) Em-Myc
lymphoma cells.
(I) Kaplan-Meier curve showing latency to tumor onset for Em-Myc lymphoma cells described in (H). The number of mice analyzed per genotype was as follows:
fl/fl, n = 15; D/D+Ctrl, n = 12; D/D+D17/20-1, n = 14; D/D +D17/20-2, n = 14; and D/D+1792, n = 15.
*p < 0.05; **p < 0.01.
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We next examined the impact of miR-17/20 on LKB1 expres-
sion in lymphoma cells. LKB1 protein levels were elevated
in D/D Em-Myc lymphoma cells compared to control cells
(Figure 5D). Stk11 mRNA levels were unaffected by deletion
of miR-1792 (Figure 5E), suggesting a mechanism of trans-
lational suppression of LKB1 mRNA by miR-17. In contrast,
LKB1 protein levels were reduced in Raji cells ectopically
expressing miR-1792 (Figure 5F). Lymphoma cells lacking
miR-17 and -20 expression (D17,20) displayed elevated
LKB1 expression similar to miR-1792-deficient lymphomas,
whereas addback of the entire miR-1792 cluster potently
reduced LKB1 protein levels in Em-Myc lymphoma cells
(Figure 5G).
miR-1792 Regulates mTORC1 Signaling in Lymphoma
through LKB1 Silencing
LKB1 is a tumor suppressor mutated in a number of human can-
cers and plays a central regulatory role in tumor metabolic and
cell growth control through downstream effects on AMPK and
mTOR signaling (Shackelford and Shaw, 2009). One prediction
of our findings was that miR-1792 may influence these
pathways through suppression of LKB1-dependent signaling.
Deletion of miR-1792 promoted an increase in basal AMPK
signaling, as determined by increased AMPKa phosphorylation
at Thr-172 and increased phosphorylation of the AMPK targets
ULK1 (Ser-555) and Raptor (Ser-792) in D/D lymphoma cells
(Figure 6A). mTORC1 pathway activity, as determined by rS6
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Figure 5. The Tumor Suppressor LKB1 Is a Target of miR-17
(A) Alignment ofmiR-17 and the wild-type (WT) 30 UTR of mouse Stk11. The putative recognition site for themiR-17 seed family in the Stk11 30 UTR is shown in
boldface. The sequence of the mutant (MUT) Stk11 30 UTR used in subsequent experiments is shown.
(B) 293T cells expressing FLAG-Ago2 (293T-Ago2) were transfected with empty vector (EV) or luciferase reporter constructs for the short (S1) or long (L1) variants
of the mouse Stk11 30 UTR containing either the wild-type (WT) or mutated (MUT) miR-17 family recognition site as in (A). Cells were co-transfected with (+) or
without (–) a miR-17x4 expression plasmid. Shown is the mean ± SEM for the FLuc/RLuc ratio for triplicate samples, normalized to control cells (EV).
(C) Immunoblot of FLAG-LKB1 protein expression in 293T-Ago2 cells co-transfected with (+) or without (–) a miR-17x4 expression plasmid and FLAG-LKB1
expression plasmids lacking the 30 UTR (D), or containing theWT or MUT 30 UTR sequence fused to the Stk11 CDS. Shown are protein levels for FLAG-LKB1 and
FLAG-Ago2 for the S1 (top) and L1 (bottom) Stk11 30 UTR isoforms.
(D) Immunoblot for LKB1 expression in fl/fl and D/D Em-Myc lymphoma cells.
(E) Relative expression of Stk11 mRNA in fl/fl and D/D Em-Myc lymphoma cells.
(F) Immunoblot for LKB1 expression in Raji cells expressing control vector (Ctrl) or ectopic expression of miR-1792 (1792).
(G) Immunoblot for LKB1 expression in miR-17/20-deficient Em-Myc lymphoma cells (+D17/20).
**p < 0.01; ***p < 0.001.
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and 4EBP phosphorylation, was decreased in D/D lymphoma
cells (Figure 6B). Similar patterns of increased AMPK activity
and decreased mTORC1 activity were observed in lymphoma
cells specifically lacking miR-17 and -20 (D17/20, Figure 6C),
implicating the miR-17 seed family as a mediator of these
signaling changes. Reducing LKB1 levels in D/D lymphoma cells
by stable short hairpin RNA (shRNA) expression (Figure 6D)
reversed the effects of miR-1792 deletion on AMPK and
mTORC1 pathway activity (Figure 6E).
LKB1 Suppression bymiR-17 Dictates Metabolic
Reprogramming and Tumorigenic Potential of Myc+
Lymphomas
We next examined the contribution of miR-17/20-dependent
suppression of LKB1 to themetabolic reprogramming that drives
Myc+ lymphoma growth. Silencing LKB1 increased metabolic
enzyme expression in D/D lymphoma cells compared to D/D
cells transducedwith a control shRNA hairpin (Figure 7A). The re-
covery ofmetabolic gene expression in LKB1 shRNA-expressing
D/D lymphoma cells correlated with increased ECAR and OCR
levels (Figure 7B), increased glucose consumption and lactate
production (Figure S6A), and increased glutaminolysis (Fig-
ure S6B) in these cells. We next culturedD/D lymphoma cells ex-
pressing control or LKB1 shRNAs with either U-[13C]-glucose
(Figures 7C and S6C) or U-[13C]-glutamine (Figures 7D and
S6D). Silencing LKB1 in D/D lymphomas restored the defects
in central carbon metabolism normally seen in these cells and
was characterized by a re-emergence of Warburg metabolism
(13C-glucose to lactate conversion, Figure 7C) and increased
contribution of both glucose and glutamine to the TCA cycle
(Figures 7C, 7D, S6C, and S6D).
Finally, we examined whether silencing LKB1 was sufficient to
rescue the tumorigenic potential of lymphoma cells lackingmiR-
1792. Expression of shRNAs targeting LKB1 reversed the pro-
liferative defect of D/D lymphoma cells in vitro (Figure 7E). When
injected into nude mice, D/D lymphoma cells expressing LKB1
shRNA (D/D+shLKB1) formed palpable lymph node tumors
with latency similar to wild-type Em-Myc lymphomas expressing
miR-1792 (fl/fl) (Figure 7F), despite the fact that these cells
lacked expression of any mature miR-1792-derived miRNAs.
These data indicate that the effects of miR-1792 loss on cell
metabolism and tumor growth can be overcome simply by dis-
rupting LKB1 signaling, highlighting the miR-17-LKB1 circuit as
a key regulator of tumor metabolism and growth.
DISCUSSION
Myc is among the most implicated genes in human cancer (Zack
et al., 2013) and has been shown to coordinate multiple cellular
behaviors in support of malignancy (Dang, 2012). Here, we
describe a new paradigm for Myc-dependent metabolic re-
programming involving the polycistronic miRNA miR-1792.
Using isogenic Myc-dependent lymphoma cells lacking miR-
1792, we demonstrate that miR-1792 is a critical regulator
of metabolic reprogramming in Myc+ tumors. We show that
miR-1792 is required to sustain both glycolytic and oxidative
metabolism and promote multiple anabolic pathways required
for tumor growth, while amplifiedmiR-1792 expression, which
is observed in many tumor types, is sufficient for cell autono-
mous upregulation of tumor metabolic activity. Our data impli-
cate the miR-17 seed family (comprising miR-17 and miR-20)
as the key regulatory element of miR-1792 that influences
both metabolic reprogramming and the oncogenic potential of
Myc-dependent lymphomas through negative regulation of the
LKB1 tumor suppressor. Our results establish metabolic reprog-
ramming as a central function for miR-1792 and implicate
metabolic control as an essential part of the oncogenic activity
of this miRNA cluster.
Previous work has established miR-1792 as an onco-
genic miRNA cluster through its ability to promote tumor cell
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Figure 6. miR-1792 Regulates AMPK and
mTORC1 Activity through LKB1
(A) Immunoblot for AMPK (total and phospho-T172),
ULK (total and phospho-S555), and Raptor (total
and phospho-S792) protein levels in fl/fl and D/D
Em-Myc lymphoma cells.
(B) Immunoblot of mTORC1 pathway activation
targets in fl/fl and D/D Em-Myc lymphoma cells.
Shown are protein levels for rS6 (total and phospho-
S235/236) and 4E-BP1 (total and phospho-S65),
with actin levels assessed as a loading control.
(C) Immunoblot for AMPK and mTORC1 activation
in miR-17/20-deficient Em-Myc lymphoma cells
(+D17/20) cultured as in (A).
(D) Immunoblot of LKB1 protein levels in control
(fl/fl), or miR-1792-deficient (D/D) Em-Myc lym-
phoma cells expressing control (Ctrl) or LKB1-spe-
cific shRNAs (LKB1).
(E) Immunoblot of AMPK and mTORC1 pathway
activation in control (fl/fl) or D/D Em-Myc lymphoma
cells expressing control (Ctrl) or LKB1-specific
shRNAs (LKB1) as in (D). Shown are protein levels
for AMPK (total and phospho-T172) and 4E-BP1
(total and phospho-T37/46).
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proliferation, cell viability, and angiogenesis while inhibiting
cellular differentiation and senescence (Dews et al., 2006; Olive
et al., 2010, 2013). Our data extend the regulatory repertoire of
miR-1792 to include many of the core metabolic processes
in cancer. Although Myc can influence specific metabolic nodes
such as glutaminolysis through suppression of miRNAs targeting
metabolic enzymes (Gao et al., 2009), our data indicate thatmiR-
1792 functions broadly to support Myc-dependent metabolic
programs. Loss of miR-1792 in Em-Myc lymphoma cells leads
to reduced transcription of core bioenergetic pathway genes
(glycolysis; TCA cycle; OXPHOS) while simultaneously altering
anabolic pathways (pentose phosphate pathway; biosynthesis
of serine, aspartate, and glutamine; purine and pyrimidine meta-
bolism) and ribosome biogenesis. This global reduction in meta-
bolic pathway gene expression is coupled to reduced nutrient
consumption and processing, including glucose and glutamine,
which serve as two major carbon sources for lymphoma growth.
Although miR-1792 cooperates with Myc to promote tumor
aggressiveness (He et al., 2005; Mu et al., 2009; Olive et al.,
2009), recent work has demonstrated Myc-independent roles
for miR-1792 in tumor maintenance (Li et al., 2014). Our data
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Figure 7. miR-17/20-Dependent Control of
LKB1 Dictates Metabolic and Tumorigenic
Potential of Myc+ Lymphoma
(A) Immunoblot for metabolic enzyme expression
in control (fl/fl) or D/D Em-Myc lymphoma cells
expressing control (Ctrl) or LKB1-specific shRNAs
(LKB1).
(B) ECAR and OCR of control (fl/fl, white) or D/D
Em-Myc lymphoma cells expressing control (Ctrl,
black) or LKB1-specific shRNAs (LKB1) as in (A).
Shown are two independent LKB1 shRNA clones
(dark gray, shLKB1-1; light gray, shLKB1-2).
(C) Relative abundance of lactate, citrate, and
glutamate in control (fl/fl) or D/D Em-Myc lym-
phoma cells expressing the indicated shRNAs.
Cells were cultured for 2 hr in medium containing
U-[13C]-glucose and unlabeled glutamine, and the
proportion of 13C-labeled (black bar) or unlabeled
(12C, white bar) metabolites as determined by
GC-MS is shown.
(D) Relative abundance of glutamate, citrate, and
aspartate in D/D Em-Myc lymphoma cells cultured
with U-[13C]-glutamine. The proportion of 13C-
labeled (gray bar) or unlabeled (12C, white bar)
metabolites is shown.
(E) Growth curve of fl/fl (red) or D/D Em-Myc lym-
phoma cells expressing control (Ctrl, black) or
LKB1-specific shRNAs (shLKB1-1, dashed line;
shLKB1-2, green).
(F) Kaplan-Meier curve showing latency to tumor
onset for control (fl/fl, n = 14) and miR-1792-
deficient Em-Myc lymphoma cells (D/D, n = 9), or
D/D lymphomas expressing control (Ctrl, n = 10) or
LKB1-specific (LKB1-1, n = 13; LKB1-2, n = 12)
shRNAs.
**p < 0.01; ***p < 0.001.
indicate that miR-1792 expression in-
fluences almost 50% of the Myc-regu-
lated transcriptome in Myc+ lymphomas.
Included in this regulation are a majority of metabolic pathway
genes previously established as Myc targets (Lin et al., 2012a;
Wang et al., 2011), suggesting that many of the effects on meta-
bolic reprogramming ascribed toMyc route throughmiR-1792.
Theseobservations counter theargument that the reducedmeta-
bolism of miR-1792-deficient (D/D) and miR-17/20-deficient
(D17,20) lymphoma cells is simply a by-product of reduced cell
size and/or proliferation but rather reflects the action of the clus-
ter on global metabolic gene expression. Given the broad effect
of miR-1792 loss on metabolic gene expression, it is unlikely
that miR-1792 directly regulates these genes through direct
miRNA:mRNA pairing. We speculate that miR-1792 functions
to reinforceMyc-dependent metabolic reprogramming indirectly
by broadly regulating the expression of transcription factors (or
other regulators) involved in metabolic reprogramming.
Processing of primarymiR-1792 (pri-miR-1792) transcripts
results in differential expression of mature miRNA species in tis-
sues (Du et al., 2015), with miR-17, -20, and -92 being the most
abundantmaturemiRNAs produced from themiR-1792 cluster
in the lymphoma cells tested. Evidence shows that miR-17 is
often the most expressed miRNA of the cluster in tumors
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(Knudsen et al., 2015; Yu et al., 2010). Lymphoma cells lacking
miR-17 and -20 (D17,20) display increased LKB1 expression,
decreased mTORC1 activity, and deficiencies in glycolytic
and oxidative metabolism identical to tumor cells lacking miR-
1792. Beyond its role in cancer, miR-1792 plays important
roles in other biological processes including hematopoietic cell
development, stem cell renewal, and axial patterning (Olive
et al., 2013). Based on our data, we hypothesize that metabolic
regulation is a central function of miR-17 family miRNAs under
both normal and pathological conditions.
Our finding that LKB1 is repressed by miR-17 family miRNAs
establishes a regulatory link between oncogenic Myc signaling
and the LKB1 tumor suppressor pathway. LKB1 has wide-
ranging impact on tumor growth and metabolism, in part by
modulating AMPK and mTORC1 activity (Shackelford and
Shaw, 2009). Reduced LKB1 signaling promotes the develop-
ment of tumors with high mTORC1 activity and an aggressive
metabolic phenotype (Dupuy et al., 2013; Faubert et al.,
2014; Shaw et al., 2004). Somatic inactivating mutations in
LKB1 are observed in many cancers, including 30% of non-
small cell lung cancer (NSCLC) cases (Gill et al., 2011). How-
ever, biallelic loss of LKB1 is rare among tumors with inactivat-
ing LKB1 mutations. Rather, haploinsufficiency of LKB1, similar
to other tumor suppressors including Tsc2, Pten, and Smad4, is
sufficient to promote tumorigenesis (Yoo et al., 2002), arguing
that gene dosage is critical for LKB1-dependent tumor sup-
pression. In this regard, miR-1792-dependent post-trans-
criptional regulation of LKB1 may help fine-tune its tumor
suppressor functions. This has clear implications for the tumor-
igenic potential of Myc+ tumors, as silencing LKB1 reverses the
severe metabolic and growth defects of lymphoma cells lacking
miR-1792.
Our results indicate that post-transcriptional regulation of
LKB1 by miRNAs can allow tumor cells to bypass LKB1-medi-
ated growth suppression without the need for inactivating
STK11 mutations. This raises the possibility that miRNA-
dependent tuning of LKB1 levels may be a general mechanism
for balancing cellular bioenergetics and cell growth in cancer,
and may contribute to the pathophysiology of LKB1-regulated
diseases such as Peutz-Jeghers syndrome. It is possible that
endogenous miRNAs in addition to miR-17 are capable of
silencing LKB1 in tumor cells and that miRNAs targeting other
components of the LKB1 complex, such as miR-451 (Godlew-
ski et al., 2010), may exert similar effects on tumor metabolism
by influencing LKB1-dependent signaling. miR-17 and -20
belong to a larger miRNA family that includes miR-93, -106a,
and -106b, all sharing a common seed sequence (50-AAA
GUG-30). Interestingly, miR-106a and -106b, which are
also encoded by miRNA clusters (miR-106a363 and miR-
106b25, respectively), are also associated with oncogenesis
(Conkrite et al., 2011; Landais et al., 2007), although our data
suggest that these miRNAs do not compensate for the loss of
miR-1792 in the lymphoma cells examined here. Whether
related miR-17 family members also influence LKB1 expres-
sion and/or tumor metabolism remains to be determined.
Together our data highlight a central role for miR-1792 in
balancing both metabolic advantage and growth potential in
cancer.
EXPERIMENTAL PROCEDURES
Cell Lines, DNA Constructs, and Cell Culture
The generation of Em-Myc Cre-ERT2+;miR-1792fl/fl lymphoma cells has been
described previously (Mu et al., 2009). Em-Myc cells were cultured on a layer of
irradiated Ink4a-null MEF feeder cells in DMEM and IMDMmedium (50:50 mix)
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and
b-mercaptoethanol. Raji cells were cultured in RPMI medium supplemented
with 10% FBS and 2 mM glutamine. Retroviral-mediated gene transfer into
lymphoma cells was conducted as previously described (Faubert et al., 2013).
For growth assays, cells were seeded at a density of 1 3 105 cells/ml in
3.5-cmdishes, and cell countswere determined via trypanblue exclusion using
a TC20 Automated Cell Counter (Bio-Rad). For viability measurements, cells
were stained with Fixable Viability Dye eFluor 780 (eBioscience) and analyzed
using a Gallios flow cytometer (Beckman Coulter) and FlowJo software (Tree
Star). Cell size was determined by forward scatter using flow cytometry.
Seahorse Analysis and Metabolic Assays
OCR and ECAR were determined using an XF96 Extracellular Flux Analyzer
(Seahorse Bioscience) using established protocols (Faubert et al., 2014;
Vincent et al., 2015a). For media metabolite determination, cells were cultured
for 2 days, and culture medium was analyzed for extracellular metabolites
(glucose, glutamine, lactate, and ammonia) using a BioProfile Analyzer
(NOVA Biomedical) as previously described (Vincent et al., 2015a). Metabolic
parameters were assessed in lymphoma cells undergoing logarithmic growth
and standardized to cell number.
For metabolomics experiments using 13C-labeled glucose or glutamine, lym-
phoma cells (3–5 3 106 per 3.5-cm dish) were cultured for 2 hr in glucose- and
glutamine-free DMEM/IMDM (50:50 mix) containing 10% dialysed FBS (Wisent
BioProducts) andeitheruniformly labeled [13C]-glucoseor [13C]-glutamine (Cam-
bridge Isotope Laboratories). 12C-glutamine (2 mM) or -glucose (25 mM) were
added back to the culture medium depending on the tracer used. Cells were
washed twice with saline and then lysed in ice-cold 80% methanol, sonicated,
derivatized as tert-butyldimethylsilyl (TBDMS) esters, and analyzed by GC-MS
using previously described protocols (Dupuy et al., 2013; Faubert et al., 2014;
McGuirketal., 2013).Metaboliteabundancewasexpressed relative toan internal
standard (D-myristic acid) and normalized to cell number. Additional experi-
mental details are described in Supplemental Experimental Procedures.
Immunoblotting, Quantitative Real-Time PCR, and RNA Sequencing
Lymphoma cell lines were subjected to SDS-PAGE and immunoblotting using
CHAPS and AMPK lysis buffers as previously described (Faubert et al., 2013).
Primary antibodies against hexokinase 2, aldolase, LDHA, GLS2, b-actin,
4EBP (total, phospho-T36/47, and phospho-S65), rS6 (total and phospho-
S235/236), ULK (total and phosphor-S555), Raptor (total and phospho-
S792), AMPKa (total and phospho-T172), and FLAG-tag were obtained from
Cell Signaling Technology. Primary antibody against LKB1 (Ley 37D/G6) was
from Santa Cruz Biotechnology.
For qPCR quantification of mature miRNAs, Qiazol was used isolate RNA,
miRNEasyMini kit was used to purify miRNAs and total mRNA, and cDNA syn-
thesized using the miScript II RT kit (QIAGEN). qPCR was performed using the
SensiFAST SYBR Hi-ROX kit (Bioline) and an AriaMX Real Time Pcr system
(Agilent Technologies). miScript primer assays (QIAGEN) were used to detect
mature miRNAs of themiR-1792 cluster, with miRNA expression normalized
relative to U6 RNA levels. RNA preparation and library construction for RNA
sequencing was conducted as previously described (Jha et al., 2015).
Libraries were sequenced using a HiSeq 2500 (Illumina) using 40 bp by
10 bp pair-end sequencing. Gene set enrichment analysis (GSEA) on RNA-
seq data was conducted using the gage function and non-parametric Kolmo-
gorov-Smirnov test from the GAGE R Bioconductor package (Luo et al., 2009).
Network integration of RNA-seq and metabolite datasets was conducted as
previously described (Jha et al., 2015). Additional experimental details are
described in Supplemental Experimental Procedures.
30 UTR Cloning and Validation
30 UTR isoforms for mouse Stk11 were determined by 30 RACE as previously
described (Wu et al., 2010). GeneArt DNA fragments (Life Technologies) for
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either the wild-type Stk11 30 UTR or harboring a mutated miR-17 seed region
(bases 2–8 in the seed region) were cloned into the XhoI/XbaI sites of the
pmirGLO vector (Promega). 293T cells (105 cells/well) stably expressing
FLAG-Ago2 (Valdmanis et al., 2012) were transfected with individual
pmirGLO-30 UTR constructs with or without co-transfection of a miR-17
expression plasmid (miR-17x4) (Hong et al., 2010). Cells were lysed 48 hr
post-transfection, and the ratio of luciferase to renilla luciferase activity deter-
mined using a Dual-Glo Luciferase assay kit (Promega) and a FLUOstar
Omega plate reader. FLAG-tagged LKB1 expression constructs were gener-
ated by PCR amplification of the full-length LKB1 coding sequence from
Em-Myc lymphoma RNA, using sequence specific primers to amplify inserts
with short or long forms of the Stk11 30 UTR.
Tumor Xenograft Assays
Lymphoma cells were resuspended in Hank’s balanced salt solution (HBSS)
and injected intravenously (106 cells/mouse in 200 ml) into CD-1 nude mice
(Charles River Laboratories). Tumor onset was monitored by palpation of
inguinal and axillary lymph nodes, and tumor-free survival scored as the
time elapsed between injection and first detection of palpable tumors as
previously described (Faubert et al., 2013). All procedures were carried out
in accordance with guidelines of the Canadian Council on Animal Care, as
approved by the Animal Care Committee of McGill University.
Statistical Analysis
Statistics were determined using paired Student’s t test, ANOVA, or log-rank
(Mantel-Cox) using Prism software (GraphPad) unless otherwise stated.
Data are calculated as the mean ± SEM for biological triplicates and the
mean ± SD for technical replicates unless otherwise stated. Statistical signifi-
cance is represented in figures by *p < 0.05; **p < 0.01; ***p < 0.001; ****p <
0.0001.
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